S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:MTEM

Molecular Templates - MTEM Stock Forecast, Price & News

$0.54
+0.01 (+1.88%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.52
$0.55
50-Day Range
$0.52
$0.80
52-Week Range
$0.48
$4.45
Volume
79,023 shs
Average Volume
195,797 shs
Market Capitalization
$30.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.83

Molecular Templates MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
607.6% Upside
$3.83 Price Target
Short Interest
Healthy
0.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.43mentions of Molecular Templates in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.52) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

230th out of 1,047 stocks

Pharmaceutical Preparations Industry

96th out of 512 stocks

MTEM stock logo

About Molecular Templates (NASDAQ:MTEM) Stock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

See More Headlines
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Company Calendar

Last Earnings
11/15/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
261
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$3.83
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+607.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-83,010,000.00
Net Margins
-231.40%
Pretax Margin
-230.40%

Debt

Sales & Book Value

Annual Sales
$38.70 million
Book Value
$0.07 per share

Miscellaneous

Free Float
40,348,000
Market Cap
$30.52 million
Optionable
Not Optionable
Beta
1.14

Social Links


Key Executives

  • Dr. Eric E. Poma Ph.D. (Age 50)
    CEO, Chief Scientific Officer & Director
    Comp: $839.67k
  • Ms. Jason S KimMs. Jason S Kim (Age 47)
    Pres & COO
    Comp: $600.41k
  • Dr. Roger J. Waltzman M.B.A. (Age 54)
    M.D., Chief Medical Officer
    Comp: $594.17k
  • Mr. Sean McLennan (Age 51)
    Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
  • Ms. Megan C. Filoon
    Gen. Counsel & Sec.
  • Mr. Kurt Elster (Age 55)
    Exec. VP of Corp. Devel.
  • Dr. Jack Higgins Ph.D. (Age 42)
    Exec. VP of Operations & Head of Manufacturing
  • Dr. Erin Willert Ph.D. (Age 40)
    Exec. VP of R&D
  • Dr. Jen-Sing Liu Ph.D. (Age 59)
    Exec. VP of Manufacturing
  • Mr. Michael Dowd
    Sr. VP of Project & Alliance Management













MTEM Stock - Frequently Asked Questions

Should I buy or sell Molecular Templates stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MTEM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTEM, but not buy additional shares or sell existing shares.
View MTEM analyst ratings
or view top-rated stocks.

What is Molecular Templates' stock price forecast for 2023?

2 equities research analysts have issued 12 month target prices for Molecular Templates' stock. Their MTEM share price forecasts range from $1.00 to $9.00. On average, they predict the company's stock price to reach $3.83 in the next twelve months. This suggests a possible upside of 607.6% from the stock's current price.
View analysts price targets for MTEM
or view top-rated stocks among Wall Street analysts.

How have MTEM shares performed in 2022?

Molecular Templates' stock was trading at $3.92 at the beginning of 2022. Since then, MTEM stock has decreased by 86.2% and is now trading at $0.5417.
View the best growth stocks for 2022 here
.

Are investors shorting Molecular Templates?

Molecular Templates saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 429,100 shares, a decline of 19.6% from the October 31st total of 533,500 shares. Based on an average daily trading volume, of 105,500 shares, the days-to-cover ratio is presently 4.1 days. Approximately 1.0% of the shares of the company are short sold.
View Molecular Templates' Short Interest
.

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our MTEM earnings forecast
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.16. The biotechnology company had revenue of $2.38 million for the quarter, compared to analyst estimates of $15.69 million. Molecular Templates had a negative net margin of 231.40% and a negative trailing twelve-month return on equity of 226.71%.

When did Molecular Templates' stock split?

Shares of Molecular Templates reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.11%), Renaissance Technologies LLC (1.03%), Kingsbury Capital Investment Advisors LLC (0.53%), Two Sigma Advisers LP (0.45%) and Two Sigma Investments LP (0.39%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $0.54.

How much money does Molecular Templates make?

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $30.53 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83,010,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does Molecular Templates have?

The company employs 261 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.

This page (NASDAQ:MTEM) was last updated on 12/2/2022 by MarketBeat.com Staff